Ponatinib Hydrochloride
(poh-NA-tih-nib HY-droh-KLOR-ide) This page contains brief information about ponatinib hydrochloride and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
| US Brand Name(s): |  | Iclusig |
| | ||
| | ||
| FDA Approved: | | Yes |
FDA Approval for Ponatinib Hydrochloride
Use in CancerPonatinib hydrochloride is approved to treat:
It is used in patients who cannot be treated with or have not gotten better with other tyrosine kinase inhibitors.
More About Ponatinib HydrochlorideDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research ResultsClinical Trial Results: New Drug Shows Promise Against Drug-Resistant Leukemias - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trials Accepting PatientsFind Clinical Trials for Ponatinib Hydrochloride - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top